(FLGT) Fulgent Genetics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(FLGT) Fulgent Genetics, Inc. Complete Analysis Pack
Fulgent Genetics Business Model Canvas: Strategy in Focus
Unlock the full strategic blueprint behind Fulgent Genetics, Inc.’s business model. This concise Business Model Canvas shows how the company creates value, serves customers, and generates revenue in a fast-moving diagnostics market. Get the full version for deeper insight and smarter strategic decisions.
Partnerships
Helio Health, Inc. alliance
Fulgent Genetics, Inc. partners with Helio Health, Inc. on blood-based early cancer detection, extending Fulgent Genetics, Inc. beyond tissue and sequencing assays into screening. The alliance links test development to commercialization, but Fulgent Genetics, Inc. has not publicly disclosed 2025/2026 partner revenue or test-volume figures.
Hospitals and medical institutions
Hospitals and medical institutions are Fulgent Genetics, Inc.’s core referral base for oncology panels, rapid whole genome testing, and inherited disease testing. With about 6,100 U.S. hospitals, these ties help Fulgent embed ordered tests into routine care and drive recurring specimen flow.
Insurance companies and payors
Insurance companies and payors are key to Fulgent Genetics, Inc. because reimbursement rules decide whether high-complexity genetic tests and molecular diagnostics get ordered at scale. Strong payer coverage helps keep clinical test volumes steadier across the menu, while weak coverage can slow adoption and pressure revenue mix.
Fellow laboratories
Fellow laboratories are a useful partner channel for Fulgent Genetics, Inc., because smaller labs can outsource advanced sequencing and pathology work instead of duplicating costly equipment, staff, and validation. This lets Fulgent capture reference and overflow testing while helping partners meet demand fast.
That model fits a market where lab-developed tests and outsourced diagnostics keep expanding, and it helps Fulgent turn specialized capacity into recurring service volume.
- Outsourced advanced testing
- Lower capex for partner labs
- Reference and overflow revenue
Government and municipal agencies
Government and municipal agencies have used Fulgent Genetics, Inc. for diagnostic testing, including COVID-19 work, which fits public-sector demand that is large, contract-based, and fast-moving. In 2024, Fulgent Genetics, Inc. reported about $280 million in revenue, so these deals help diversify demand beyond hospitals and insurers.
- Large, time-sensitive contracts
- Supports COVID-19 testing demand
- Diversifies payer mix
Fulgent’s Growth Engine: Hospitals, Payors, Labs, and Public Contracts
Fulgent Genetics, Inc. leans on hospitals, payors, and labs to move oncology, hereditary, and rapid genome tests into routine care. In 2024, Fulgent Genetics, Inc. reported about $280 million in revenue, while 2025/2026 partner revenue was not publicly disclosed. Public-sector contracts, including COVID-19 work, add volume and spread risk.
| Partner | Role |
|---|---|
| Hospitals | Referrals |
| Payors | Coverage |
| Labs | Overflow |
| Govt. | Contracts |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas of Fulgent Genetics, Inc. covering its genomics-driven customers, channels, value proposition, and revenue model.
Customizable Excel Spreadsheet
Quickly spot Fulgent Genetics’ key pain points and value drivers with a clear, editable one-page business snapshot.
Reference Sources
Lists trusted sources behind Fulgent Genetics claims, making the research credible and easier to use in decisions.
Activities
Genetic testing and molecular diagnostics
Fulgent Genetics runs a broad clinical testing engine across six core areas: oncology panels, carrier screening, exome, whole genome, mutation, and repeat-expansion testing. In 2024, the Company generated about $285 million in total revenue, showing how this diagnostics menu remains the main driver of its business.
COVID-19 diagnostic testing
Fulgent Genetics, Inc. uses next-generation sequencing, RT-PCR, and antigen tests for SARS-CoV-2, widening its lab menu into infectious disease diagnostics. The COVID-19 surge showed it could scale fast: pandemic testing revenue topped $1.8 billion in 2021, proving it could meet urgent public-health demand.
Advanced laboratory analyses
Fulgent Genetics, Inc. uses flow cytometry, FISH, IHC, and cytogenetics to support cancer diagnosis, malignancy tracking, and chromosome checks across hematopoietic and solid tumor testing. These methods matter in a market where the American Cancer Society projected about 2.0 million new U.S. cancer cases in 2024, so demand for deep tumor profiling stays high.
Assay development and validation
Fulgent Genetics, Inc. keeps assay development and validation central to its menu, adding tests like rapid whole genome sequencing for NICU and PICU patients, front-line ataxia sequencing, and newborn genetic panels. In 2025, this steady pipeline helped keep its clinical offering broad and current, which matters in rare disease and acute-care settings where speed can change care.
- Rapid whole genome testing for critical care
- Ataxia sequencing for first-line workups
- Newborn panels for early detection
- Ongoing validation keeps tests clinically relevant
Consumer genetic testing operations
Picture Genetics adds patient-initiated testing to Fulgent Genetics, Inc., so the Company has to run consumer ordering, sample intake, lab processing, and digital result delivery. This channel broadens Fulgent Genetics, Inc. beyond provider-led diagnostics and supports a more direct customer relationship; in FY2025, that mix helps diversify revenue access and use the same lab network more efficiently.
- Patient-initiated orders
- Sample-to-result workflow
- Expands direct consumer reach
Fulgent Expands Its Test Menu Across Clinical and Consumer Genetics
Fulgent Genetics, Inc. focuses on building and validating its clinical test menu, with oncology, rare-disease, and critical-care sequencing as core work. It also runs consumer-directed testing through Picture Genetics, using the same lab network to move from order intake to result delivery.
| Key activity | FY2025 note |
|---|---|
| Test development | Broadens clinical menu |
| Direct-to-consumer workflow | Uses shared lab capacity |
What You See Is What You Get
Business Model Canvas
The Fulgent Genetics, Inc. Business Model Canvas previewed here is the exact document you’ll receive after purchase. This is not a sample or mockup—it's a direct snapshot from the final file. Once you complete your order, you’ll get the same fully formatted document, ready to download, edit, and use immediately.
Resources
Clinical laboratory infrastructure
Fulgent Genetics centers its clinical lab infrastructure in Temple City, California, where physical lab capacity drives high-complexity molecular, genetic, and pathology testing. This asset is core to revenue generation because it supports rapid sample throughput and test menus across thousands of assays.
Sequencing and testing platforms
Fulgent Genetics, Inc. relies on next-generation sequencing, RT-PCR, antigen workflows, and pathology methods to run a broad test menu across oncology, inherited disease, infectious disease, and reproductive health. These platforms are core assets, because they support both high-complexity testing and faster turnarounds for routine diagnostics.
In its latest reported year, Fulgent Genetics, Inc. said testing volume remained spread across multiple disease areas, with molecular diagnostics still the main engine of the platform. That mix lets the Company adjust capacity and keep one lab stack serving many payers and clinical use cases.
Scientific and technical workforce
Fulgent Genetics, Inc. depends on laboratory scientists, molecular experts, and technical staff to run genetic testing and pathology assays, where expert interpretation drives accuracy and turnaround time. Skilled personnel are a core resource because they support quality control, complex test review, and the company’s high-throughput lab operations.
Assay portfolio and intellectual know-how
Fulgent Genetics, Inc. uses a broad assay portfolio across oncology, carrier screening, exome, genome, and rare disease, and its proprietary test design and validation know-how helps keep results fast, accurate, and hard to copy. That mix is a core moat in a market where panel depth and clinical utility drive repeat business.
- Broad menu across key genetic use cases
- Proprietary design and validation know-how
- Strong market differentiation and stickiness
Picture Genetics brand and digital workflow
Picture Genetics gives Fulgent Genetics, Inc. a direct-to-patient channel that lowers friction in consumer testing. The brand and digital ordering flow support self-service access, helping extend Fulgent beyond provider labs into a patient-led model; Fulgent reported $319.0 million in 2024 revenue, showing scale to support this channel.
- Direct-to-patient access
- Digital ordering lowers friction
- Supports self-service testing
Fulgent’s Lab, Assay Platform, and Talent Drive Growth
Fulgent Genetics, Inc. key resources are its Temple City lab base, broad assay platform, and skilled molecular staff, which together support high-complexity testing across oncology, inherited disease, and infectious disease. The Company also uses Picture Genetics for direct-to-patient access, widening demand beyond provider channels.
| Key resource | Why it matters |
|---|---|
| Temple City lab | Core test throughput |
| Assay stack | NGS, RT-PCR, pathology |
| Revenue scale | $319.0 million, 2024 |
Value Propositions
Broad multi-disease test menu
Fulgent Genetics offers one provider for a broad multi-disease menu, with over 18,000 genetic and molecular tests spanning oncology, inherited conditions, newborn screening, rare diseases, and COVID-19. That breadth helps labs, health systems, and clinicians cut vendor sprawl and source many diagnostics from one platform.
Rapid whole genome testing for critical care
Fulgent Genetics, Inc. offers rapid whole genome testing for critically ill infants in NICU and PICU units, giving clinicians broad genetic answers in about 24 to 48 hours instead of weeks. This speed matters in urgent pediatric care, where early diagnosis can change treatment for the small share of infants who need intensive care.
Oncology profiling and malignancy monitoring
Fulgent Genetics supports oncology profiling and malignancy monitoring with solid tumor molecular profiling, hematopoietic testing, flow cytometry, FISH, IHC, and cytogenetics, built for high-complexity cancer workflows. These tools help identify tumors and track disease over time, which matters when a single case can need multiple assay types across diagnosis and follow-up.
Consumer access through Picture Genetics
Picture Genetics gives Fulgent Genetics, Inc. a direct-to-consumer path for select genetic tests, so patients can start testing without a provider-order bottleneck. This widens access to genetic information and helps Fulgent Genetics, Inc. reach consumers faster, while reducing reliance on clinic-only ordering.
- Direct patient initiation
- Consumer-friendly access
- Less provider dependence
Research and specialty testing depth
Fulgent Genetics, Inc. offers whole exome, whole genome, mutation, repeat expansion, and research service tests, giving customers access to five advanced assay types beyond standard panels. That depth supports research labs and specialty clinicians that need broader variant detection and harder-to-diagnose cases.
It helps Fulgent stay relevant with high-complexity users; in 2025, its value came from a menu built for advanced analysis, not just routine screening.
- Five advanced test types
- Beyond standard panel limits
- Fits research and specialty care
18,000+ Tests and 24–48 Hour Genomics for Faster Answers
Fulgent Genetics, Inc. turns breadth and speed into its core value: more than 18,000 tests across oncology, rare disease, newborn screening, and molecular diagnostics, plus 24–48 hour rapid whole genome results for critically ill infants. It also adds direct-to-consumer access through Picture Genetics and advanced assay depth for complex cases.
| Value driver | Data point |
|---|---|
| Test breadth | 18,000+ tests |
| Rapid pediatric WGS | 24–48 hours |
Customer Relationships
Contract-based institutional accounts
Fulgent Genetics, Inc. builds contract-based institutional accounts with hospitals, laboratories, payors, and public-sector buyers through testing agreements and ongoing service support. This setup drives recurring, high-volume lab work, which fits a low-friction, account-managed model built for repeat orders and coordinated workflows.
Provider-supported test selection
In fiscal 2025, Fulgent Genetics kept provider-supported test selection at the center of its customer ties, helping clinicians order the right specialty assay and move cleanly through result workflows. That matters because the relationship depends on professional trust and clinical utility, not just a broad test menu.
Direct-to-consumer self-service
Picture Genetics gives Fulgent Genetics, Inc. a direct line to patients, with no provider referral needed. That self-service model depends on simple ordering, clear reports, and plain-language updates, because in FY2025 consumer trust and repeat use come down to low-friction access and easy-to-read results.
Reimbursement and billing support
Fulgent Genetics, Inc. needs strong reimbursement and billing support because test uptake often hinges on eligibility checks, prior authorization, and claims handling. By guiding providers and patients through coverage questions and denials, it cuts delays and lowers out-of-pocket friction, which helps keep orders moving.
- Handle insurance eligibility fast
- Support claims and appeals
- Reduce patient billing surprises
Recurring diagnostic relationships
Fulgent Genetics' customer relationships are recurring, not one-off: cancer, inherited disease, and therapy-monitoring patients often need repeat panels over months or years. That makes retention and physician trust central, because each follow-up order can turn one case into a multi-test stream.
- Repeat orders lift lifetime value.
- Trust lowers switching.
- Monitoring drives steady volume.
Fulgent’s FY2025 Growth Hinged on Repeat Testing and Easy Access
In FY2025, Fulgent Genetics, Inc. kept customer ties split between 2 paths: provider-led clinical accounts and Picture Genetics direct-to-consumer orders. The model depends on repeat testing, fast billing help, and clear results, because trust and low friction drive reorder volume.
| Customer tie | FY2025 signal | Why it matters |
|---|---|---|
| Provider accounts | Recurring test orders | Supports repeat clinical volume |
| Picture Genetics | Direct patient access | Lowers ordering friction |
Channels
Physician and hospital ordering
Physician and hospital ordering is Fulgent Genetics, Inc.'s main route to market, because most clinical tests are ordered through doctors, hospitals, and medical institutions and then fit into standard oncology, neonatal, and inherited-disease care paths. This channel is core to adoption, since it reaches patients at the point of care where testing decisions are made.
Laboratory referral network
Fellow laboratories refer specialized or overflow genetic and molecular work to Fulgent Genetics, Inc., letting them serve patients without building every assay in-house. This channel widens reach into advanced testing demand and supports a broader, higher-complexity test mix.
Picture Genetics online access
Picture Genetics online access gives Fulgent Genetics, Inc. a direct consumer channel, letting patients engage with the brand and start testing online. This supports patient-driven genetic testing by lowering friction and reaching users who prefer to order from home.
Government and corporate procurement
Government and corporate procurement gives Fulgent Genetics, Inc. a route to large, repeat testing contracts with agencies, cities, and employers. In 2024, Fulgent Genetics, Inc. reported $274.6 million in revenue, and this channel can help fill surge demand through programmatic deployments.
- Best for large, standardized test buys
- Supports rapid surge response
- Fits broad public and enterprise programs
Electronic reporting and results delivery
Fulgent Genetics delivers diagnostic results through digital laboratory workflows and clinical reporting systems, so customers can get fast, secure access without waiting on manual handoffs. That faster delivery supports repeat use, because clear electronic reporting fits busy labs and clinicians who need results they can act on quickly.
- Fast access to results.
- Digital workflow delivery.
- Supports repeat ordering.
Fulgent Genetics’ Multi-Channel Sales Engine Drives Fast, Repeatable Growth
Fulgent Genetics, Inc. sells mainly through physician and hospital orders, lab-to-lab referrals, direct-to-consumer Picture Genetics, and government or corporate contracts. Digital reporting closes the loop, so results reach clinicians and patients fast and support repeat testing; 2024 revenue was $274.6 million.
| Channel | Role |
|---|---|
| Physicians/hospitals | Main clinical route |
| Labs | Referral overflow |
| Picture Genetics | Direct consumer |
| Gov./corporate | Bulk contracts |
Customer Segments
Hospitals and medical institutions
Hospitals and medical institutions are key Fulgent Genetics, Inc. customers for oncology, pediatric, and inherited disease testing. These buyers need specialized laboratory support for complex cases and rapid, high-volume workflows, which keeps Fulgent close to clinical teams that need precise genetic results.
Fellow laboratories
Fellow laboratories are a key customer segment when they need specialized reference testing, and Fulgent Genetics, Inc. can help by outsourcing complex assays from its broad test menu. This segment values depth, fast turnaround, and technical reliability, especially for hard-to-run molecular and genetic tests.
Insurance companies and payors
Insurance companies and payors shape access and reimbursement for Fulgent Genetics, Inc. testing, so they are central to diagnostic volume. With private insurance covering 65.4% of U.S. people in 2023, Fulgent has to meet coverage rules, prior auth, and documentation standards to get paid and keep tests in use.
Government and municipal bodies
Government and municipal bodies buy Fulgent Genetics, Inc. testing for public health, outbreak response, and core operations, with the segment proving most important during COVID-19 when public testing demand surged. It also fits large institutional screening programs, where one contract can cover thousands of workers, students, or residents at once.
- Public health and operational testing
- Key during COVID-19 surge
- Large institutional programs
Major corporations and direct patients
Major corporations can buy Fulgent testing for employee screening or wellness programs, while direct patients use Picture Genetics for self-ordered DNA tests. This mix broadens Fulgent beyond provider channels and taps both B2B and consumer demand; in FY2025, that reach matters as employer and self-pay testing can scale faster than clinic referrals.
- Employer-sponsored testing
- Self-initiated Picture Genetics orders
- Less reliance on provider channels
Fulgent Genetics’ Key Buyers: Hospitals, Payors, and Public Agencies
Fulgent Genetics, Inc. serves five main buyers: hospitals, reference labs, payors, public agencies, and corporations or self-pay patients. The split spans clinical care, outsourced testing, public health, and direct-to-consumer orders, so demand depends on reimbursement and large institutional contracts.
| Customer segment | Why it buys |
|---|---|
| Hospitals | Oncology and rare disease tests |
| Payors | Coverage and reimbursement control |
| Public bodies | Public health and screening |
Cost Structure
Laboratory reagents and consumables
Fulgent Genetics, Inc. uses sequencing reagents, assay kits, and other consumables for each test, so this cost line moves with volume and sits inside direct lab expense. In FY2025, the company’s laboratory operations still carried these variable inputs as a core cost driver, which means higher test counts raise spend almost one-for-one.
Personnel and scientific labor
Fulgent Genetics, Inc. needs lab staff, scientists, bioinformatics teams, and support staff because clinical diagnostics is hands-on and expertise-heavy. Payroll is a major fixed cost base, and in FY2025 the company still had to fund these people even as demand shifted, which keeps personnel tied closely to service capacity and turnaround time.
Sequencing equipment and facility costs
Laboratory operations at Fulgent Genetics depend on costly sequencing platforms and controlled lab space, so equipment depreciation, maintenance, and facility rent remain a major fixed cost. In 2024, the business reported about $319 million of revenue, but high-complexity testing still required heavy infrastructure spending to keep throughput and quality high.
R and D and assay validation
Fulgent Genetics, Inc. spends on R and D and assay validation to keep its test menu current and clinically reliable. This cost base includes research, clinical validation, and quality systems; in 2024, Fulgent reported $274.4 million of revenue, so even modest menu gains can matter.
- New tests need clinical validation
- Quality systems protect assay accuracy
Compliance, billing, and logistics
Clinical labs like Fulgent Genetics, Inc. must fund compliance, billing, and sample handling before they book revenue, so these are core cost drivers in scaled diagnostics. Shipping, accessioning, and report delivery add more overhead, and even one late sample or billing error can raise rework costs and slow cash collection.
- Compliance and billing are fixed-cost heavy
- Sample logistics adds per-test cost
- Accessioning and report delivery need scale
Fulgent Genetics’ FY2025 Cost Drivers: Volume, Labs, and R&D
Fulgent Genetics, Inc. has a cost structure led by variable test inputs and fixed lab overhead, so reagent use, sample logistics, and billing scale with volume while sequencing platforms, lab space, and staff stay largely fixed in FY2025. R and D, validation, and compliance also remain core costs, and the company reported about $319 million of revenue in 2024.
| Cost item | FY2025 driver |
|---|---|
| Reagents and kits | Per-test variable cost |
| Lab staff | Fixed payroll base |
| Sequencers and space | Depreciation, rent, upkeep |
| R and D | Validation and menu refresh |
Revenue Streams
Clinical genetic test fees
Clinical genetic test fees are Fulgent Genetics, Inc.'s main revenue line, with pay-per-test billing for carrier screening, exome, genome, and inherited disease panels sold to providers and institutions. Revenue scales with each ordered assay, so volume and test mix drive results more than one-time licensing or service fees.
Oncology and molecular diagnostics revenue
Oncology and molecular diagnostics are a core revenue stream for Fulgent Genetics, Inc., led by oncology panels, solid tumor profiling, and hematopoietic testing. These high-complexity assays have clear clinical value and support recurring demand across cancer care pathways, making them a steady source of sales.
COVID-19 diagnostic revenue
By FY2025, Fulgent Genetics, Inc.'s COVID-19 diagnostic revenue had largely faded as SARS-CoV-2 demand normalized, after the company had monetized NGS, RT-PCR, and antigen testing during peak public-health and institutional demand. This stream showed how Fulgent Genetics, Inc. could scale rapid-response diagnostics fast, then exit as the market shrank.
Direct-to-consumer Picture Genetics sales
Picture Genetics generates revenue from patient-initiated test orders, so Fulgent Genetics, Inc. sells directly to consumers instead of waiting on provider referrals. That gives Fulgent Genetics, Inc. a retail-style genetics channel with broader reach and more control over pricing and customer acquisition.
- Direct consumer-paid testing
- Less referral dependence
- Retail-style genetics channel
Research and specialty laboratory services
Fulgent Genetics, Inc. earns revenue from research service tests and advanced lab work, including flow cytometry, FISH, IHC, cytogenetics, and specialty sequencing. This line broadens the mix beyond standard clinical panels and helps smooth demand swings across end markets.
- Research and specialty tests add revenue diversity.
- Advanced methods support higher-value lab work.
- Service mix reduces panel-only dependence.
Fulgent’s Growth Now Hinges on Genetics, Oncology, and DTC Testing
Fulgent Genetics, Inc. relies on pay-per-test clinical genetics, oncology diagnostics, and specialty lab services; revenue rises with assay volume and test mix. FY2025 COVID-19 sales were minimal, so the mix shifted back to inherited disease, cancer, and direct-to-consumer testing through Picture Genetics.
| Stream | FY2025 role |
|---|---|
| Clinical genetics | Main fee driver |
| Oncology diagnostics | Recurring demand |
| Picture Genetics | Direct-to-consumer sales |
| COVID-19 | De minimis |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.